Roivant Sciences Ltd.
Key statistics
from XBRL data in SEC filingsAI briefing
from the latest 10-K, 10-Q and 8-K eventsRoivant Sciences is a biopharmaceutical holding company developing a pipeline of late-stage drug candidates through subsidiary 'Vants', with a near-term FDA decision on brepocitinib in dermatomyositis.
What they do
Roivant develops and commercializes medicines through nimble subsidiaries ('Vants') that focus on specific drug candidates. Its pipeline includes brepocitinib (JAK1/TYK2 inhibitor) for multiple indications, IMVT-1402 (anti-FcRn monoclonal antibody) for IgG-mediated autoimmune diseases, and mosliciguat (inhaled sGC activator) for pulmonary hypertension. The company also holds minority stakes and royalty rights in other entities, including Arbutus and Datavant.
Revenue drivers
- Product revenue — Sole revenue source; minimal and declining (FY2026 revenue $8.3M vs $29.1M in FY2025), as no products are marketed yet. Most revenue relates to prior collaborations or other arrangements.
- Milestone and royalty rights from Dermavant sale — Retained rights to future milestones and royalties from the 2024 sale of Dermavant; no current revenue recognized.
- Genevant settlement proceeds (non-recurring) — Genevant received $950M from Moderna in July 2026 (initial payment under $2.25B settlement) and files lawsuits against Pfizer/BioNTech, but these are not operating revenue.
Recent performance
For Q1 FY2027 (June 30, 2026), revenue was $1.4M, down from $2.5M in the prior quarter. Full-year FY2026 revenue fell to $8.3M from $29.1M in FY2025, while net loss widened to $299.8M from $172.0M. Operating cash flow remained negative at $750.3M for FY2026. The company held $1.25B in cash and equivalents at June 30, 2026, excluding the $950M Genevant payment received in July.
Strategy
Management plans to continue in-licensing mid/late-stage drug candidates (multiple per year) and advance its pipeline through Vants. Key near-term priorities include preparing for brepocitinib launch, executing on IMVT-1402 registrational trials, and progressing mosliciguat. The company also seeks to maximize value from its Genevant litigation and milestone rights.
Risks
- Regulatory and launch risk for brepocitinib — FDA decision on brepocitinib in dermatomyositis is expected in Q3 2026; any delay or non-approval would delay revenue and impact share value.
- Clinical trial risks across pipeline — Multiple Phase 2/3 trials (NIU, CS, LPP, IMVT-1402 indications, mosliciguat) have topline readouts through 2026-2028; failures would reduce pipeline value.
- Reliance on external partners for revenue — Revenue is minimal and dependent on deals like the Dermavant sale and Genevant settlement, not on product sales, making cash flow unpredictable.
- Subsidiary ownership dilution and public market exposure — Roivant owns only 55% (basic) of Immunovant and 20% of Arbutus, so minority shareholders and market volatility affect consolidated results.
Outlook
Management expects brepocitinib launch by end of September 2026, with topline data from NIU, PH-ILD, and CLE studies in H2 2026. Enrolment in the CS Phase 3 trial is ongoing with data expected in 2028. The company plans to continue in-licensing new drugs and expects to reach profitability, supported by $3.9B in consolidated cash (including Genevant proceeds).